Compare iShares MSCI United Kingdom (FTSE) (EWU) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI United Kingdom (FTSE) vs IDEXX Laboratories, Inc. — how do they compare? iShares MSCI United Kingdom (FTSE) trades at $46.48 (market cap $3.62B), while IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B). The key difference: IDEXX Laboratories, Inc. is far larger — about 11.2× iShares MSCI United Kingdom (FTSE)'s market cap, and iShares MSCI United Kingdom (FTSE) is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI United Kingdom (FTSE) for 46 Days and IDEXX Laboratories, Inc. for 46 Days on average.
| EWU | IDXX | |
|---|---|---|
Market Cap | $3.62B | $40.43B |
Volume | 923,896 | 692,164 |
Sector | Broad Market / Factor | Health |
52-Week High | $49.39 | $766.68 |
52-Week Low | $41.34 | $504.70 |
Typical Hold Time | 46 Days | 46 Days |
Enterprise Value | — | $41.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWU trades at $46.445, up 1.12% on the day, but faces a bearish technical outlook with 16 sell signals versus 3 buy signals. The stock is trading near key support levels at $46, with RSI indicators showing mixed signals. Recent UK market volatility driven by rising gilt yields and inflation concerns creates headwinds for this UK-focused ETF.
The outlook remains cautious given the bearish technical momentum and macroeconomic pressures from rising UK borrowing costs. Investment opportunity exists for contrarian investors if support holds, but risks include further interest rate hikes and economic uncertainty in the UK market.
IDEXX Laboratories (IDXX) trades at $519.87, up 2.61% on the day, with a bearish technical signal from moving averages but strong fundamentals including a 25.03% net income margin and consistent earnings beats. Revenue grew to $4.3B in 2025, and the company recently acquired CoVetAI to enhance veterinary workflow intelligence, signaling strategic expansion.
The stock's outlook is supported by robust profitability and analyst consensus, but faces headwinds from technical weakness and potential market volatility. With a $665 price target implying significant upside, the primary risks include competitive pressures and execution of growth initiatives amid economic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares MSCI United Kingdom (FTSE)
EWU is a country-specific ETF that tracks the performance of the United Kingdom equity market. It provides exposure to large and mid-sized UK companies, with significant weightings in financials, energy, and healthcare, including Shell, AstraZeneca, and HSBC.
Read more on EWU →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
